Association Between Urinary Flow Rate and Cognition in the Elderly: A Cross-Sectional Study

Yifan Li  
West China Hospital of Sichuan University

Linghui Deng  
National Clinical Research Center for Geriatrics and Center of Biomedical big data, West China Hospital of Sichuan University

Shi Qiu  
West China Hospital of Sichuan University

Boyu Cai  
West China Hospital of Sichuan University

Sheng Wang  
West China Hospital of Sichuan University

Xingyu Xiong  
West China Hospital of Sichuan University

Kun Jin  
West China Hospital of Sichuan University

Lu Yang (✉ wycleflue@163.com)  
West China Hospital of Sichuan University

Pro Birong Dong  
National Clinical Research Center for Geriatrics and Center of Biomedical big data, West China Hospital of Sichuan University

Research Article

Keywords: urinary flow rate, cognitive impairment, National Health and Nutrition Examination Survey (NHANES), elderly population

Posted Date: January 3rd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1114298/v1

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Age-related lower urinary tract symptoms (LUTS) is a common disease in the elderly. The reduction of urinary flow rate (UFR) as an assessment of LUTS is associated with cognitive impairment. The association between UFR and cognitive performance has not been studied to date.

Methods

We used data from the 2011 to 2014 U.S. National Health and Nutrition Examination Survey (NHANES). Finally, 2,724 participants aged 65-80 with available data on UFR and cognitive assessments were included. The cognitive function assessment used the digit symbol substitution test (DSST), Animal Fluency Test (AFT) and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) immediate recall test. Multivariate logistic regressions were used to assess the association between UFR (exposure) and cognitive performance (outcome). Additionally, to ensure the reliability of data analysis, we converted UFR into categorical variables through tertile and then calculated the P for trend.

Results

Among 2,724 participants, the mean (SD) age was 69.26 (6.65) years, and 54.56% were women. After adjusting for covariates, UFR showed a positive correlation with DSST score ($\beta = 2.00$, [95%Cl:1.20-2.80], $P<0.0001$), AFT score ($\beta = 0.57$, [95%Cl:0.28-0.87], P=0.0001), CERAD immediate score($\beta = 0.24$, [95%Cl:0.01-0.47], $P=0.0435$). In addition, we found a similar linear trend when UFR was regarded as a categorical variable (tertile) (P for trend <0.0001(both in AFT and DSST); P for trend =0.0403 in CERAD immediate test).

Conclusions

The decrease of UFR is related to cognitive decline in the elderly, which may suggest that UFR may be a clinical marker of predicting cognitive decline.

Key Points

- This study aims to study the correlation between lower urinary tract dysfunction and the decline of cognitive function in the elderly. The decrease of urinary flow rate may become a risk factor for predicting cognitive impairment in the elderly.
- To investigate the association between UFR and cognitive performance, which can provide a clinical marker for predicting cognitive decline in elderly.
Introduction

The global population aging has largely led to the increase of morbidity and disability\(^1\). Age-related cognitive decline begins in middle age and continues with time\(^2\). Elderly cognitive impairment has a great impact on the daily life of patients and their families, increases the mortality of the elderly, and brings a huge burden to the society\(^3–5\). In view of the occult incidence of cognitive decline and the slow progress to dementia, and the fact that there is no effective treatment for this disorder at present, it is very important to screen high-risk groups and find early cognitive decline markers for primary prevention\(^6\).

Urinary flow rate (UFR) represents the amount of urine excreted from the urethra per unit time in a natural state, which is mainly influenced by detrusor contraction strength and bladder outlet resistance\(^7\). As a common noninvasive examination, the determination of UFR has the advantages of rapidity, low cost and high repeatability, which is widely used in the preliminary screening of lower urinary tract symptoms (LUTS). As far as we knew, the low UFR was considered to be a bladder dysuria, which is manifested as the underactive bladder (UAB) caused by detrusor underactivity\(^8\). According to the definition of the International Continence Society, the detrusor underactivity refers to bladder weakness or prolonged bladder emptying time due to decreased contractility\(^9\). Many previous studies have shown that poor urination is caused by both myogenic and neurogenic mechanisms\(^10–13\). Therefore, as a disease characterized by neurologic impairment, cognitive impairment plays an important role in urination.

At present, some studies have proved that the cognitive decline of the elderly is related to the dysfunction of urination. Jellinger\(^14\) found that LUTS, which consist of storage (frequency, urgency, nocturia) and voiding symptoms (delayed urination, poor or prolonged urine flow), were common in patients with Parkinson's disease (PD) (prevalence 27% - 85%). Picillo et al\(^15\) also mentioned that dysuria is an early marker of progression of PD, and suggested that urinary dysfunction can be used to predict the development of the disease, which may represent a valuable variable in neuroprotective clinical trials. However, so far, there is no relevant predictor to indicate the occurrence of cognitive impairment.

In this study, we aimed to examined the association between UFR and cognitive performance based on the U.S. National Health and Nutrition Examination Survey (NHANES) database, which objective to provide predictive indicators for the occurrence of cognitive impairment in the elderly in order to prevent and control earlier.

Materials And Methods

Data Collection and participants selection

The NHANES study is a nationally representative study of population in the United States, which is also a cross-sectional survey based on a national sample of non-institutionalized population in the USA. It is conducted by the U.S. National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). The survey consist of three main parts. Initial screening of qualified participants
through the questionnaire. Then, extensive interviews are conducted, including age, gender, race, medical history and health status. What is more, physical examination and clinical evaluation are performed in specially designed mobile examination centers (MECs). In the process of data acquisition, all interviewers have received the training plan and reached the required standards. NHANES started in 1999 and is an ongoing annual survey with data published every 2 years and made publicly available online. This study gained Institutional Review Board (IRB; project identification code protocol #2011-17) approval by the NCHS in line with the revised Helsinki Declaration. Informed consent was provided by all study participants before the data collection and examination procedures. More NHANES data and information are available at https://www.cdc.gov/nchs/nhanes/index.htm.

Participants from the NHANES were included in this population-based cross-sectional research. There were 19,932 participants in the NHANES from two 2-year survey cycles: 2011-2012 and 2013-2014. We screen participants according to the exclusion criteria listed below: (1) subjects without cognitive performance score (n =16,997 ); (2) subjects without UFR data (n =166 ); (3) subjects with missing data for covariate (n=45 ). Eventually, 2,724 eligible individuals of the NHANES survey were included in our study (Figure 1).

The whole informed consents from each eligible participant were obtained after explaining the whole process of the research. All experimental methods were performed in accordance with the relevant guidelines and regulations of the CDC.

Measurement of Urinary Flow Rate

The UFR was measured by uroflowmetry (mL/min). The calculation formula of UFR is \( UFR = \frac{V}{t} \) where \( V \) is the volume of the present urine sample and \( t \) is the time duration between the former urination and the present urine collection. The participants had to record their last urination time before coming to the MECs. Then, at the centers, they would record the voiding time and volume of the urine sample and calculate the UFR for three times. The specimens were collected in different containers to guaranteeing enough data for various analyses. The composite UFR (mL/min) was measured by dividing the total urine volume collected by the total time covered by all collected voids.

Measurement of Cognitive Function

The following 3 cognitive function measurements designed to assess a wide range of neurocognitive function across a variety of demo graphic backgrounds were studied: the Digit Symbol Substitution Test (DSST), the Animal Fluency Test (AFT) and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) immediate recall test. The three assessment methods of cognitive function score are detailed in the Supplementary File.

Covariates
Multivariate model contains variables that may confound the association between UFR and cognitive function. For covariates, continuous variables included age (year). Categorical variables included: sex (male; female), poverty income ratio (PIR)(<1; ≥1), body mass index (BMI) (<25; ≥25<30; ≥30), alcohol intake per week (0; 1; 2), marital status (married or living with partner; living alone) , smoking status (never; former; current) and comorbidity index (0, 1, 2, 3, 4, 5). BMI values were calculated by dividing participants' weight (in kilograms) by their height (in square meters)\[19\]. Diabetes mellitus, congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema) and hypertension, cancer consisted of comorbid conditions. The number of subjects reported conditions were then combined to generate an ordinal comorbidity index\[20\].

Statistical analysis

The statistical analysis was performed according to the CDC analytical reporting guidelines for complex NHANES data analysis (https://wwwn.cdc.gov/nchs/nhanes/tutorials/default.aspx). A sample weight was assigned to each person participating in NHANES. Therefore, we accounted for masked variance and used the proposed recommended weighting methodology. Continuous variables were expressed as mean ± standard deviation. Categorical variables were expressed in frequency or as a percentage. Weighted linear regression model (for continuous variables) or weighted chi-square test (for categorical variables) were used to calculate the differences among different UFR groups (tertiles). To investigate whether UFR is correlated with cognitive function in selected participants, our statistical analysis consisted of two main steps.

First, weighted multivariate logistic regression model were employed. We estimated three models: crude model, no covariates were adjusted; model I, only adjusted for gender, age and BMI data; in the final model (model II), model I + other covariates presented in Table 1 (i.e. PIR; marital status; comorbidity index; alcohol intake per week and smoking status).

Moreover, the subgroup analyses were then performed using weighted stratified logistic regression models to further determine the correlation between UFR and cognitive function. To ensure the robustness of data analysis, we did the sensitivity analysis.

All analyses were performed using the statistical software packages R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empower stats.com, X&Y Solutions, Inc., Boston, MA). All P values less than 0.05 (two-sided) were considered statistically significant.

Results

Baseline characteristics of participants

The weighted distribution of selective participants sociodemographic characteristics and other related covariates for the selected 2,724 NHANES participants from 2011 to 2014, according to UFR tertiles, is shown in Table 1. The average age of the participants was 69.26±6.65, and 54.56% were women. Among
different tertile groups (T1-T3), there was no obvious difference in the following distributions: smoking status, BMI, comorbidity index and alcohol intake per week. We found that both UFR declined and cognitive performance scores (DSST, AFT and CERAD immediate recall test) decreased with age (p<0.0001).

**Multivariate Logistic Regression Analysis**

Associations between UFR as a continuous variable and cognitive performance (DSST, AFT and CERAD immediate recall test) is demonstrated in Table 2. Our multivariate logistic regression analysis showed UFR was positively correlated with DSST, AFT and CERAD immediate recall test in the crude model (AFT: β=1.07, 95%CI: [0.76–1.39], P<0.0001; DSST: β=3.83, 95%CI: [2.91–4.74], P<0.0001; CERAD immediate: β=0.59, 95%CI: [0.34–0.83], P<0.0001) (see Table 2). In the adjusted model I (adjusted by gender, age and BMI) (AFT: β=0.64, 95%CI: [0.33–0.94], P<0.0001; DSST: β=2.34, 95%CI: [1.49–3.20], P<0.0001; CERAD immediate: β=0.28, 95%CI: [0.05–0.52], P=0.0180) and model II (adjusted by gender; age; smoking status; alcohol intake per week; marital status; BMI; ratio of family income to poverty; comorbidity index) (AFT: β=0.57, 95%CI: [0.28–0.87], P<0.0001; DSST: β=2.00, 95%CI: [1.20–2.80], P<0.0001; CERAD immediate: β=0.24, 95%CI: [0.01–0.47], P=0.0435), the results remained stable.

In addition, to further test the correlation between UFR and cognitive function, participants were divided into three groups according to UFR (0.01-0.51, 0.51-0.92 and 0.92-3.45). Regarding UFR as a categorical variable (tertile), we found the similar trend (AFT: P for trend <0.0001; DSST: P for trend <0.0001; CERAD immediate: P for trend =0.0403) (see Table 2).

**Subgroup Analyses**

Table 3 shows the results of our subgroup analysis. We found that after adjusting for potential confounding factors, the interaction test had no significant effect on age (grouped by 65 years old), gender, smoking status, marital status, comorbidity index, and alcohol intake per week (P> 0.05), except for BMI and PIR. However, due to the large difference in the number of patients between groups, and the lack of clinical significance. We think that there is still a positive relationship between UFR and cognitive ability.

**Discussion**

In the elderly population of the United States, we found that the UFR decline was positively correlated with the decrease of cognitive function after adjusting for a variety of potential confounders in men and women.

Previous studies have noted the high incidence of LUST in age-related cognitive impairment\textsuperscript{21–23}. Consistent with our findings, some previous studies have found that LUST caused by cognitive impairment in the elderly are common in Alzheimer's disease (AD), PD and Lewy body syndrome\textsuperscript{24–26}. In addition, multiple system atrophy (MSA) is another cognitive disorder in the elderly with typical LUST,
which is urinary retention\cite{27,28}. Sakakibara et al used pressure-flow analysis in PD during urination, and the results showed that detrusor activity was weak during urination (40% of men; 66% of women)\cite{29}.

The nervous system controls many essential aspects of the normal urination cycle (storage and urination). Especially important are cognition (e.g., decision-making, anticipation, perception of environmental/social context and conscious perception of sensation), sensory nerve activity and autonomic nerve functions (e.g., regulation of detrusor and sphincter) and motor function (e.g., mobility, balance and dexterity). Neurologic functions work together to ensure that urine storage and voiding reflect timings and environment appropriately, which are completely controlled voluntarily\cite{30}. The neurogenic dysuria in the elderly may come from two ways: one is the disturbance of sensory consciousness, the other is the degeneration of nervous system, which leads to the loss of the function of the muscles. By default, the lower urinary tract remains in "store" mode during bladder filling. When the bladder is full, there is a "switch" to "urinate" mode. Default mode network is the key functional basis of PD cognitive impairment, for PD patients, there is the dysfunction of the corticobasal ganglia associative areas nigrostriatal and mesocortical dopamine (DA) depletion with impairment of the frontostriatal circuitry, which is important for executive problems\cite{31}. On the other hand, detrusor underactivity is an important cause of dysuria in MSA. It may be caused by degeneration of primary motor cortex (PMC) and locus coeruleus, pontobronchial raphe and cerebellar vermis, all of which regions are considered to be important areas of brain autonomic control\cite{32}.

This study has multiple advantages. This is the first study to explore the relationship between UFR and cognitive impairment in the elderly, so as to provide a feasible marker for clinical prediction of cognitive impairment in the elderly. Second, the multi-ethnic, nationally representative data from NHANES enable our findings to be extrapolated to a broader population.

However, this study still has several imitations. First of all, NHANES is a cross-sectional study that examines cognitive scores and UFR at a specific point in time, rather than continuously collecting data over a long period of time. As a single measurement may produce biased results, causality can not be established. Secondly, although we use three cognitive assessment methods, we still can not cover the overall cognitive ability. Accompanying tests, such as mini mental state examination (MMSE), help to assess cognitive function more comprehensively. Thirdly, we used the method in the NHANES database to calculate the average urine flow rate, which can not represent the detrusor contraction and diastolic pressure values and the maximum urinary flow rate. The combination of the average UFR and the peak UFR certainly provides more comprehensive urodynamic studies, but the peak UFR requires more complex calculation with uroflowmetry. However, the average UFR data can be used as a reference index of urinary reflex and the overall bladder muscle function. In addition, previous comparative studies have used the average UFR\cite{16}, which provide us with methods that can be used for reference. In the future, more clinical studies are needed to determine the relationship between UFR and cognitive decline, which may provide a new method for predicting cognitive impairment in the elderly.
Conclusion

Using the NHANES database, this study found a positive correlation between UFR and cognitive ability in the elderly after adjusting for potential confounding factors, which may suggest that UFR can be used as a marker to predict cognitive impairment in the elderly. In order to better understand the pathophysiology of this correlation, further high-quality studies are needed.

Abbreviations

LUTS: lower urinary tract symptoms; UFR: urinary flow rate; NHANES: National Health and Nutrition Examination Survey; DSST: digit symbol substitution test; AFT: Animal Fluency Test; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; SD: standard deviation; UAB: underactive bladder; PD: Parkinson's disease; NCHS: National Center for Health Statistics; CDC: Centers for Disease Control and Prevention; MECs: mobile examination centers; BMI: body mass index; PIR: poverty income index; AD: Alzheimer's disease; DA: dopamine; MSA: multisystem atrophy; PMC: primary motor cortex; MMSE: mini mental state examination.

Declarations

Acknowledgments

The authors appreciate the American Centers for Disease Control and Prevention for conducting the survey and for providing the data available online freely, and all the participants for providing these data.

Authors’ contributions

Yifan Li: Writing- Original draft preparation, Conceptualization, Investigation Linghui Deng and Shi Qiu: Methodology, Software Kun Jin: Data curation Xingyu Xiong and Sheng Wang: Software, Investigation. Birong Dong: Writing- Reviewing and Editing, Data curation Lu Yang: Writing- Reviewing and Editing, Supervision. All the authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No.81902578, 81974098, 8197032158), China Postdoctoral Science Foundation (2017M612971), Post-doctoral Science Research Foundation of Sichuan University (2020SCU12041), Post-Doctor Research Project, West China Hospital, Sichuan University (2018HXBH084), China Postdoctoral Science Foundation (2020M670055ZX), Supported by the Sichuan Science and Technology Program (20PJ039).

Availability of data and materials

The original NHANES dataset to support this study is available from the National Center for Health Statistics, https://www.cdc.gov/nchs/nhanes/index.htm.
Ethics approval and consent to participate

This study included data from NHANES 2011-14, which obtained ethics approval from the National Center for Health Statistics (Protocol #2011-17). All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki), and all participants provided their informed consent.

Consent for publication

Not applicable.

Competing interests

The authors have declared no conflicts of interest with respect to the authorship or publication of this article.

Author details

1 Department of Urology, Institute of Urology, National Clinical Research Center for Geriatrics and Center of Biomedical big data, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

2 National Clinical Research Center of Geriatrics, The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

3 West China School of Clinical Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

References

1. Anstey KJ, Dear K, Christensen H, Jorm AF. Biomarkers, health, lifestyle, and demographic variables as correlates of reaction time performance in early, middle, and late adulthood. Q J Exp Psychol A. 2005 Jan;58(1):5-21. doi: 10.1080/02724980443000232. PMID: 15881288.

2. Linghui D, Shi Q, Chi C et al. The Association Between Leukocyte Telomere Length and Cognitive Performance Among the American Elderly. Front Aging Neurosci. 2020 Oct 30;12:527658. doi: 10.3389/fnagi.2020.527658. PMID: 33192450; PMCID: PMC7661855.

3. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014 Dec 17;312(23):2551-61. doi: 10.1001/jama.2014.13806. PMID: 25514304; PMCID: PMC4269302.

4. Ferri CP, Prince M, Brayne C et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 Dec 17;366(9503):2112-7. doi: 10.1016/S0140-6736(05)67889-0. PMID: 16360788; PMCID: PMC2850264.
5. Chan KY, Wang W, Wu JJ et al; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet. 2013 Jun;8(381):2016-23. doi: 10.1016/S0140-6736(13)60221-4. PMID: 23746902.

6. Scheltens P, Blennow K, Breteler MM et al. Alzheimer's disease. Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24. PMID: 26921134.

7. Chiu HT, Kao TW, Peng TC, Chen YY, Chen WL. Average urinary flow rate and its association with handgrip strength. Aging Male. 2020 Dec;23(5):1220-1226. doi: 10.1080/13685538.2020.1740201. Epub 2020 Mar 17. PMID: 32180484.

8. Aizawa N, Igawa Y. Pathophysiology of the underactive bladder. Investig Clin Urol. 2017 Dec;58(Suppl 2):S82-S89. doi: 10.4111/icu.2017.58.S2.S82. Epub 2017 Nov 13. PMID: 29279880; PMCID: PMC5740034.

9. Abrams P, Cardozo L, Fall M et al; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. PMID: 11857671.

10. Taylor JA 3rd, Kuchel GA. Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc. 2006 Dec;54(12):1920-32. doi: 10.1111/j.1532-5415.2006.00917.x. PMID: 17198500.

11. Gilpin SA, Gilpin CJ, Dixon JS, Gosling JA, Kirby RS. The effect of age on the autonomic innervation of the urinary bladder. Br J Urol. 1986 Aug;58(4):378-81. doi: 10.1111/j.1464-410x.1986.tb09089.x. PMID: 3756405.

12. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol. 1993 Nov;150(5 Pt 2):1681-95. doi: 10.1016/s0022-5347(17)35869-x. PMID: 8411456.

13. Ito H, Kamei J, Aizawa N et al. Preventive Effects of Long-Term Caloric Restriction on Aging Related in Vivo Bladder Dysfunction and Molecular Biological Changes in the Bladder and Dorsal Root Ganglia in Rats. J Urol. 2016 Nov;196(5):1575-1583. doi: 10.1016/j.juro.2016.05.104. Epub 2016 May 31. PMID: 27259654.

14. Jellinger KA. Neuropathology of Nonmotor Symptoms of Parkinson's Disease. Int Rev Neurobiol. 2017;133:13-62. doi: 10.1016/bs.irn.2017.05.005. Epub 2017 Jun 27. PMID: 28802920.

15. Picillo M, Palladino R, Barone P et al; PRIAMO Study Group. The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. Eur J Neurol. 2017 Jun;24(6):788-795. doi: 10.1111/ene.13290. Epub 2017 Apr 20. PMID: 28425642.

16. Wu SE, Chen WL. Exploring the Association between Urine Caffeine Metabolites and Urine Flow Rate: A Cross-Sectional Study. Nutrients. 2020 Sep 13;12(9):2803. doi: 10.3390/nu12092803. PMID: 32933151; PMCID: PMC7551421.
17. Middleton DR, Watts MJ, Lark RM, Milne CJ, Polya DA. Assessing urinary flow rate, creatinine, osmolality and other hydration adjustment methods for urinary biomonitoring using NHANES arsenic, iodine, lead and cadmium data. Environ Health. 2016 Jun 10;15(1):68. doi: 10.1186/s12940-016-0152-x. PMID: 27286873; PMCID: PMC4902931.

18. Hays SM, Aylward LL, Blount BC. Variation in urinary flow rates according to demographic characteristics and body mass index in NHANES: potential confounding of associations between health outcomes and urinary biomarker concentrations. Environ Health Perspect. 2015 Apr;123(4):293-300. doi: 10.1289/ehp.1408944. Epub 2015 Jan 27. PMID: 25625328; PMCID: PMC4384205.

19. Cheng YW, Hung CC, Kao TW, Chen WL. Beneficial relevance of vitamin D concentration and urine flow rate. Clin Nutr. 2021 Apr;40(4):2121-2127. doi: 10.1016/j.clnu.2020.09.036. Epub 2020 Oct 1. PMID: 33039156.

20. Fantus RJ, Packiam VT, Wang CH, Erickson BA, Helfand BT. The Relationship between Sleep Disorders and Lower Urinary Tract Symptoms: Results from the NHANES. J Urol. 2018 Jul;200(1):161-166. doi: 10.1016/j.juro.2018.01.083. Epub 2018 Mar 27. PMID: 29408214.

21. Barone P, Antonini A, Colosimo C et al; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009 Aug 15;24(11):1641-9. doi: 10.1002/mds.22643. PMID: 19514014.

22. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956. PMID: 18307261.

23. Yeo L, Singh R, Gundeti M, Barua JM, Masood J. Urinary tract dysfunction in Parkinson's disease: a review. Int Urol Nephrol. 2012 Apr;44(2):415-24. doi: 10.1007/s11255-011-9969-y. Epub 2011 May 7. PMID: 21553114.

24. Ransmayr GN, Holliger S, Schletterer K et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008 Jan 22;70(4):299-303. doi: 10.1212/01.wnl.0000296826.61499.26. PMID: 18209204.

25. Orme S, Morris V, Gibson W, Wagg A. Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations. Drugs Aging. 2015 Jul;32(7):559-67. doi: 10.1007/s40266-015-0281-x. PMID: 26169438.

26. Lee SH, Cho ST, Na HR, Ko SB, Park MH. Urinary incontinence in patients with Alzheimer's disease: relationship between symptom status and urodynamic diagnoses. Int J Urol. 2014 Jul;21(7):683-7. doi: 10.1111/jiu.12420. Epub 2014 Mar 4. PMID: 24593278.

27. Hahn K, Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord. 2005 Nov;20(11):1499-502. doi: 10.1002/mds.20586. PMID: 16037912.

28. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006 Jun;21(6):737-45. doi: 10.1002/mds.20867. PMID: 16570299.
29. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamics and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):600-6. doi: 10.1136/jnnp.71.5.600. PMID: 11606669; PMCID: PMC1737611.

30. Gajewski JB, Drake MJ. Neurological lower urinary tract dysfunction essential terminology. Neurourol Urodyn. 2018 Aug;37(S6):S25-S31. doi: 10.1002/nau.23758. PMID: 30614062.

31. Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist. 2004 Dec;10(6):525-37. doi: 10.1177/1073858404266776. PMID: 15534038.

32. Roy HA, Green AL. The Central Autonomic Network and Regulation of Bladder Function. Front Neurosci. 2019 Jun 13;13:535. doi: 10.3389/fnins.2019.00535. PMID: 31263396; PMCID: PMC6585191.

**Tables**

Table 1 Baseline Characteristics of Participants
| Cognitive Performance | Overall (n=2,724) | Tertile 1 (n=2,724) | Tertile 2 (n=2,724) | Tertile 3 (n=2,724) | P value |
|-----------------------|-------------------|---------------------|---------------------|---------------------|---------|
| UFR                   | 0.01-0.51         | 0.51-0.92           | 0.92-3.45           |                     |         |
| Age (years) [mean (SD)] | 69.26 ± 6.65     | 70.73 ± 6.81        | 69.18 ± 6.59        | 68.05 ± 6.31        | <0.0001 |
| Gender [%]            |                   |                     |                     |                     | <0.0001 |
| Male                  | 45.44             | 38.96               | 49.62               | 47.23               |         |
| Female                | 54.56             | 61.04               | 50.38               | 52.77               |         |
| Marital status [%]    |                   |                     |                     |                     | 0.0006  |
| Married or living with partner | 65.34         | 60.54               | 69.19               | 65.96               |         |
| Living alone          | 34.66             | 39.46               | 30.81               | 34.04               |         |
| BMI [%]               |                   |                     |                     |                     | 0.0708  |
| < 25                  | 26.19             | 26.26               | 26.44               | 25.91               |         |
| >= 25, < 30           | 37.18             | 33.71               | 37.80               | 39.64               |         |
| >= 30                 | 36.62             | 40.03               | 35.76               | 34.44               |         |
| PIR [%]               |                   |                     |                     |                     | 0.0085  |
| Below poverty (< 1)   | 8.31              | 10.71               | 6.96                | 7.46                |         |
| Above poverty (>1)    | 91.69             | 89.29               | 93.04               | 92.54               |         |
| Smoking status [%]    |                   |                     |                     |                     | 0.5115  |
| Never                 | 49.92             | 48.40               | 51.86               | 49.44               |         |
| Former                | 40.26             | 41.23               | 39.46               | 40.14               |         |
| Current               | 9.83              | 10.37               | 8.67                | 10.42               |         |
| Alcohol intake per week [%] |               |                     |                     |                     | 0.0226  |
| 0                     | 22.6              | 23.72               | 21.62               | 22.52               |         |
| 1                     | 52.7              | 55.32               | 50.49               | 52.45               |         |
| 2                     | 24.7              | 20.96               | 27.89               | 25.03               |         |
| Comorbidity index [%] |                   |                     |                     |                     | 0.1609  |
| 0                     | 29.86             | 27.71               | 29.42               | 32.15               |         |
| 1                     | 42.93             | 42.70               | 43.30               | 42.79               |         |
|                  | Mean (SD)       | Mean (SD)       | Mean (SD)       | Mean (SD)       | P value |
|------------------|-----------------|-----------------|-----------------|-----------------|---------|
| Animal Fluency Test Score Language | 18.15 ± 5.68   | 16.95 ± 5.18   | 18.40 ± 5.64   | 18.99 ± 5.95   | <0.0001 |
| DSST Scores      | 52.25 ± 16.69   | 48.54 ± 17.23   | 53.10 ± 15.85   | 54.70 ± 16.45   | <0.0001 |
| CERAD immediate  | 19.79 ± 4.45    | 19.32 ± 4.67    | 19.76 ± 4.35    | 20.22 ± 4.30    | <0.0001 |

BMI: body mass index.

PIR: poverty income ratio.

DII: dietary inflammatory index

Comorbidity index: diabetes mellitus, congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema) and hypertension, cancer consisted of comorbid conditions.

Note: Mean ± SD for continuous variables: P value was calculated by weighted linear regression model.

Number (%) for Categorical variables: P value was calculated by weighted chi-square test.

Table 2 Association between Urinary flow rate and Cognitive performance
| Exposure                                      | Urinary flow rate |
|----------------------------------------------|-------------------|
|                                              | β (95% CI), P value |
|                                              | Model 1 p Value     | Model 2 p Value | Model 3 p Value |
| Animal Fluency test score language          | n=2,724            | n=2,724         | n=2,724         |
|                                              | 1.07 (0.76, 1.39)  | <0.0001         | 0.64 (0.33, 0.94) | <0.0001 | 0.57 (0.28, 0.87) | 0.0001 |
| Animal Fluency test score language (tertiles) | 0                  | 0               | 0               |
| T1                                            | 1.50 (0.97, 2.03)  | <0.0001         | 1.08 (0.57, 1.59) | <0.0001 | 0.84 (0.35, 1.34) | 0.0009 |
| T2                                            | 2.07 (1.56, 2.59)  | <0.0001         | 1.38 (0.88, 1.88) | <0.0001 | 1.26 (0.77, 1.75) | <0.0001 |
| P for trend                                   | 1.85 (1.35, 2.35)  | <0.0001         | 1.20 (0.72, 1.68) | <0.0001 | 1.13 (0.66, 1.61) | <0.0001 |
| DSST                                          | 3.83 (2.91, 4.74)  | <0.0001         | 2.34 (1.49, 3.20) | <0.0001 | 2.00 (1.20, 2.80) | <0.0001 |
| DSST (tertiles)                               | 0                  | 0               | 0               |
| T1                                            | 4.66 (3.10, 6.22)  | <0.0001         | 3.54 (2.10, 4.98) | <0.0001 | 2.63 (1.28, 3.99) | <0.0001 |
| T2                                            | 6.15 (4.64, 7.67)  | <0.0001         | 3.86 (2.45, 5.28) | <0.0001 | 3.38 (2.06, 4.71) | <0.0001 |
| P for trend                                   | 5.42 (3.95, 6.89)  | <0.0001         | 3.21 (1.85, 4.57) | <0.0001 | 2.94 (1.66, 4.22) | <0.0001 |
| CERAD immediate                               | 0.59 (0.34, 0.83)  | <0.0001         | 0.28 (0.05, 0.52) | 0.0180 | 0.24 (0.01, 0.47) | 0.0435 |
|    | T1       | 0      | 0      | 0      |
|----|----------|--------|--------|--------|
| T2 | 0.38     | 0.0772 | 0.18   | 0.3838 |
|    | (-0.04, 0.80) |        | (-0.22, 0.57) |        | 0.05 (-0.34, 0.44) | 0.7828 |
| T3 | 0.90 (0.49, 1.31) | <0.0001 | 0.44 (0.05, 0.83) | 0.0271 | 0.37 (-0.01, 0.75) | 0.0589 |
| P  | 0.87 (0.48, 1.27) | <0.0001 | 0.43 (0.05, 0.80) | 0.0253 | 0.39 (0.02, 0.75) | 0.0403 |

95%CI: 95% Confidence interval

Model 1: no covariates were adjusted

Model 2: adjusted for gender; age; BMI

Model 3: adjusted for gender; age; smoking status; alcohol intake per week; marital status; BMI; ratio of family income to poverty; comorbidity index

UFR tertiles ranges: Tertile 1 =0.01 to 0.51; Tertile 2 =0.51 to 0.92; Tertile 3 =0.92 to 3.45

Table 3: Stratified logistic regression analysis to identify variables that modify the correlation between Urinary low rate and Cognitive performance
| Subgroup        | DSST                              |
|-----------------|-----------------------------------|
|                 | n      | Crude | P Value | Model II | P Value |
| **Gender [%]**  |        |       |         |          |         |
| Male            | 1322   | 4.14  | <0.0001 | 2.42     | 0.0006  |
|                 |        |       | (2.64, 5.64) | (1.04, 3.79) |
| Female          | 1402   | 4.08  | <0.0001 | 2.96     | <0.0001 |
|                 |        |       | (2.70, 5.47) | (1.70, 4.22) |
| P interaction   | 0.955  |       |         |          | 0.5678  |
| **Age [%]**     |        |       |         |          |         |
| <65             | 833    | 2.64  | 0.0022  | 2.15     | 0.0076  |
|                 |        |       | (0.95, 4.32) | (0.57, 3.73) |
| ≥65             | 1891   | 3.92  | <0.0001 | 3.61     | <0.0001 |
|                 |        |       | (2.67, 5.18) | (2.44, 4.79) |
| P interaction   | 0.2299 |       |         |          | 0.1439  |
| **PIR [%]**     |        |       |         |          |         |
| Below poverty   | 415    | 3.18  | 0.0160  | 1.36     | 0.2646  |
| (< 1)           |        |       | (0.60, 5.77) | (-1.03, 3.76) |
| Above poverty   | 2309   | 3.91  | <0.0001 | 2.95     | <0.0001 |
| (≥1)            |        |       | (2.82, 5.00) | (1.94, 3.96) |
| P interaction   | 0.6126 |       |         |          | 0.2294  |
| **Comorbidity index [%]** |        |       |         |          |         |
| 0               | 784    | 5.17  | <0.0001 | 3.42     | <0.0001 |
|                 |        |       | (3.34, 7.01) | (1.76, 5.09) |
| 1               | 1242   | 3.44  | <0.0001 | 2.29     | 0.0012  |
|                 |        |       | (1.91, 4.97) | (0.91, 3.68) |
| 2,3,4,5         | 698    | 3.11  | 0.0036  | 2.56     | 0.0079  |
|                 |        |       | (1.02, 5.20) | (0.67, 4.45) |
| P interaction   | 0.2526 |       |         |          | 0.5790  |
### Smoking status [%]

|        | n    | Crude | P Value  | Model II | P Value  |
|--------|------|-------|----------|----------|----------|
| Never  | 1346 | 4.79  | <0.0001  | 3.22     | <0.0001  |
|        |      | (3.32, 6.26) |          | (1.88, 4.56) |          |
| Former | 1087 | 3.13  | 0.0001   | 1.99     | 0.0066   |
|        |      | (1.54, 4.72) |          | (0.56, 3.43) |          |
| Current| 291  | 3.97  | 0.0165   | 3.23     | 0.0310   |
|        |      | (0.73, 7.20) |          | (0.30, 6.16) |          |
| P interaction | | 0.3209 |          | 0.4387 |          |

### BMI [%]

|        | n    | Crude | P Value  | Model II | P Value  |
|--------|------|-------|----------|----------|----------|
| < 25   | 734  | 5.25  | <0.0001  | 4.24     | <0.0001  |
|        |      | (3.23, 7.27) |          | (2.42, 6.07) |          |
| >= 25, < 30 | 987 | 4.98  | <0.0001  | 3.13     | <0.0001  |
|        |      | (3.27, 6.68) |          | (1.59, 4.68) |          |
| >= 30  | 1003 | 2.31  | 0.0065   | 1.27     | 0.0963   |
|        |      | (0.65, 3.97) |          | (-0.23, 2.78) |          |
| P interaction | | 0.0350 |          | 0.0376 |          |

### Alcohol intake per week [%]

|        | n    | Crude | P Value  | Model II | P Value  |
|--------|------|-------|----------|----------|----------|
| 0      | 747  | 3.58  | 0.0007   | 1.92     | 0.0410   |
|        |      | (1.51, 5.64) |          | (0.08, 3.76) |          |
| 1      | 1446 | 4.20  | <0.0001  | 2.51     | <0.0001  |
|        |      | (2.85, 5.55) |          | (1.31, 3.72) |          |
| 2      | 531  | 3.04  | 0.0467   | 2.03     | 0.0467   |
|        |      | (0.80, 5.28) |          | (0.03, 4.02) |          |
| P interaction | | 0.8355 |          | 0.8355 |          |

### Subgroup

| Subgroup | Animal Fluency test score language |
|----------|-----------------------------------|
|          | n  | Crude | P Value  | Model II | P Value  |
| Gender [%] |    |      |----------|----------|----------|
| Male     | 1322 | 1.04  | <0.0001  | 0.65     | 0.0020   |
|          |      | (0.55, 1.52) |          | (0.18, 1.11) |          |
| Female   | 1402 | 0.70  | 0.3198   | 0.46     | 0.5557   |
|                      | Estimate 1 | Estimate 2 | Estimate 3 | Estimate 4 |
|----------------------|------------|------------|------------|------------|
|                      | (0.26, 1.15) | (0.03, 0.89) |            |            |
| P interaction        | 0.3198     | 0.5557     |            |            |
| **Age [%]**          |            |            |            |            |
| <65                  | 0.54       | 0.0517     | 0.38       | 0.1598     |
|                      | (-0.00, 1.08) | (-0.15, 0.92) |            |            |
| ≥65                  | 0.84       | <0.0001    | 0.79       | 0.0001     |
|                      | (0.44, 1.25) | (0.39, 1.19) |            |            |
| P interaction        | 0.3821     | 0.2298     |            |            |
| **PIR [%]**          |            |            |            |            |
| Below poverty (< 1)  | 0.9881     | -0.34      | 0.4102     |            |
|                      | (-0.83, 0.85) | (-1.15, 0.47) |            |            |
| Above poverty (≥1)   | 0.97       | <0.0001    | 0.70       | <0.0001    |
|                      | (0.61, 1.32) | (0.36, 1.04) |            |            |
| P interaction        | 0.0389     | 0.02       |            |            |
| **Comorbidity index [%]** |            |            |            |            |
| 0                    | 1.19       | <0.0001    | 0.83       | 0.0040     |
|                      | (0.60, 1.77) | (0.26, 1.39) |            |            |
| 1                    | 0.52       | 0.0360     | 0.23       | 0.3364     |
|                      | (0.03, 1.01) | (-0.24, 0.70) |            |            |
| 2,3,4,5              | 0.95       | 0.0052     | 0.76       | 0.0204     |
|                      | (0.28, 1.62) | (0.12, 1.40) |            |            |
| P interaction        | 0.2144     | 0.2074     |            |            |
| **Smoking status [%]** |            |            |            |            |
| Never                | 0.77       | 0.0014     | 0.40       | 0.0850     |
|                      | (0.30, 1.24) | (-0.05, 0.85) |            |            |
| Former               | 0.92       | 0.0004     | 0.66       | 0.0084     |
|                      | (0.41, 1.43) | (0.17, 1.15) |            |            |
| Current              | 1.07       | 0.0433     | 0.78       | 0.1273     |
|                      | (0.03, 2.10) | (-0.22, 1.77) |            |            |
| P interaction        | 0.8321     | 0.6650     |            |            |
### BMI [%]

|               | n  | Crude | P Value | Model II | P Value |
|---------------|----|-------|---------|----------|---------|
| < 25          | 734| 0.86  | 0.0092  | 0.61     | 0.0532  |
|               |    |       | (0.21, 1.50) | (-0.01, 1.23) |         |
| >= 25, < 30   | 987| 1.01  | 0.0003  | 0.59     | 0.0282  |
|               |    |       | (0.47, 1.56) | (0.06, 1.11) |         |
| >= 30         | 1003| 0.72  | 0.0074  | 0.46     | 0.0792  |
|               |    |       | (0.19, 1.26) | (-0.05, 0.97) |         |
| P interaction |    | 0.7601|         | 0.9112   |         |

### Alcohol intake per week [%]

|               | n  | Crude | P Value | Model II | P Value |
|---------------|----|-------|---------|----------|---------|
| 0             | 747| 0.80  | 0.0177  | 0.41     | 0.2101  |
|               |    |       | (0.14, 1.47) | (-0.23, 1.05) |         |
| 1             | 1446| 0.88  | <0.0001 | 0.50     | 0.0187  |
|               |    |       | (0.45, 1.31) | (0.08, 0.92) |         |
| 2             | 531| 0.64  | 0.0838  | 0.33     | 0.3537  |
|               |    |       | (-0.08, 1.36) | (-0.36, 1.02) |         |
| P interaction |    | 0.8481|         | 0.9050   |         |

### Subgroup CERAD immediate

| Subgroup     | n   | Crude | P Value | Model II | P Value |
|--------------|-----|-------|---------|----------|---------|
| Gender [%]   |     |       |         |          |         |
| Male         | 1322| 0.83  | <0.0001 | 0.49     | 0.0090  |
|              |    |       | (0.43, 1.23) | (0.12, 0.86) |         |
| Female       | 1402| 0.49  | 0.0139  | 0.25     | 0.1649  |
|              |    |       | (0.10, 0.87) | (-0.10, 0.61) |         |
| P interaction|    | 0.2264|         | 0.3793   |         |
| Age [%]      |     |       |         |          |         |
| <65          | 833 | 0.42  | 0.0726  | 0.41     | 0.0722  |
|              |    |       | (-0.04, 0.88) | (-0.04, 0.86) |         |
| >=65         | 1891| 0.55  | 0.0018  | 0.51     | 0.0025  |
|              |    |       | (0.20, 0.89) | (0.18, 0.85) |         |
|                        | P interaction | 0.6648 | 0.7129 |
|------------------------|---------------|--------|--------|
| **PIR [%]**            |               |        |        |
| Below poverty (< 1)    | 415           | -0.03  | 0.9407 | -0.41  |
|                        |               | (-0.74, 0.68) | (-1.08, 0.27) |
| Above poverty (≥1)     | 2309          | 0.70   | <0.0001| 0.49   |
|                        |               | (0.40, 1.00) | (0.21, 0.78) |
| **Comorbidity index [%]** |               |        |        |
| 0                      | 784           | 0.95   | 0.0002 | 0.58   |
|                        |               | (0.46, 1.45) | (0.12, 1.05) |
| 1                      | 1242          | 0.58   | 0.0058 | 0.36   |
|                        |               | (0.17, 1.00) | (-0.03, 0.75) |
| 2,3,4,5                | 698           | 0.17   | 0.5458 | 0.07   |
|                        |               | (-0.39, 0.74) | (-0.46, 0.60) |
| **Smoking status [%]** |               |        |        |
| Never                  | 1346          | 0.47   | 0.0201 | 0.18   |
|                        |               | (0.07, 0.87) | (-0.20, 0.55) |
| Former                 | 1087          | 0.68   | 0.0018 | 0.44   |
|                        |               | (0.25, 1.11) | (0.03, 0.84) |
| Current                | 291           | 1.05   | 0.0183 | 0.91   |
|                        |               | (0.18, 1.93) | (0.08, 1.73) |
| **BMI [%]**            |               |        |        |
| < 25                   | 734           | 0.81   | 0.0034 | 0.63   |
|                        |               | (0.27, 1.36) | (0.11, 1.14) |
| >= 25, < 30            | 987           | 0.99   | <0.0001| 0.62   |
|                        |               | (0.53, 1.45) | (0.18, 1.05) |
| >= 30                  | 1003          | 0.15   | 0.5166 | -0.07  |
|                        |               | (-0.30, 0.60) | (-0.49, 0.36) |
| P interaction | 0.0268 | 0.0424 |
|---------------|--------|--------|

**Alcohol intake per week [%]**

|  | 747 | 0.64 | 0.0273 | 0.27 | 0.3140 |
|---|-----|------|--------|------|--------|
| 0 | (0.07, 1.20) | (0.07, 1.20) |
| 1 | 1446 | 0.77 | <0.0001 | 0.49 | 0.0066 |
| 2 | 531 | 0.07 | 0.8265 | -0.13 | 0.6538 |
| P interaction | 0.1539 | 0.1938 |

BMI: body mass index.

PIR: poverty income ratio.

DII: dietary inflammatory index

Comorbidity index: diabetes mellitus, congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema) and hypertension, cancer consisted of comorbid conditions.

Note: Number (%) for Categorical variables: P value was calculated by weighted chi-square test.

Crude: no covariates were adjusted

Model II: adjusted for gender; age; smoking status; alcohol intake per week; marital status; BMI; ratio of family income to poverty; comorbidity index

**Figures**
Figure 1

Flowchart of Participant Inclusion and Exclusion for Analysis

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• Supplementaryfile.docx